Completed PHASE2 INTERVENTIONAL 3-arm NCT00691808

Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment

A Randomized, Double-Blind, Placebo-Controlled Study to Determine Safety and Tolerability of LX6171 Oral Suspension Dosed for 28 Days in Subjects Exhibiting Age Associated Memory Impairment (AAMI)

Sponsor: Lexicon Pharmaceuticals

Conditions Age-Related Memory Disorders

Interventions LX6171 High Dose LX6171 Low Dose Placebo

Updated 7 times since 2017 Last updated: Feb 17, 2010 Started: Feb 29, 2008 Primary completion: Oct 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00691808, this PHASE2 trial focuses on Age-Related Memory Disorders and remains completed. Sponsored by Lexicon Pharmaceuticals, it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Lexicon Pharmaceuticals

Data source: Lexicon Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Utrecht, Netherlands
• Zuidlaren, Netherlands